Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

Anthony Mato; John Pagel; Catherine Coombs; Nirav Shah; Nicole Lamanna; Talha Munir; Ewa Lech-Maranda; Toby Eyre; Jennifer Woyach; William Wierda; Chan Cheah; Johnathan Cohen; Lindsey Roeker; Manish Patel; Bita Fakhri; Minal Barve; Constantine Tam; David Lewis; James Gerson; Alvaro Alencar; Chaitra Ujjani; Ian Flinn; Suchitra Sundaram; Shuo Ma; Deepa Jagadeesh; Joanna Rhodes; Justin Taylor; Omar Abdel-Wahab; Paolo Ghia; Stephen Schuster; Denise Wang; Binoj Nair; Edward Zhu; Donald Tsai; Matthew Davids; Jennifer Brown; Wojciech Jurczak

Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

Anthony Mato
, John Pagel
, Catherine Coombs
, Nirav Shah
, Nicole Lamanna
, Talha Munir
, Ewa Lech-Maranda
, Toby Eyre
, Jennifer Woyach
, William Wierda
, Chan Cheah
, Johnathan Cohen
, Lindsey Roeker
, Manish Patel
, Bita Fakhri
, Minal Barve
, Constantine Tam
, David Lewis
, James Gerson
, Alvaro Alencar

Chaitra Ujjani, Ian Flinn, Suchitra Sundaram, Shuo Ma, Deepa Jagadeesh, Joanna Rhodes, Justin Taylor, Omar Abdel-Wahab, Paolo Ghia, Stephen Schuster, Denise Wang, Binoj Nair, Edward Zhu, Donald Tsai, Matthew Davids, Jennifer Brown, Wojciech Jurczak

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	97-101
Number of pages	5
Journal	British Journal of Haematology
Volume	197
Publication status	Published - Apr 2022
Externally published	Yes
Event	2nd Annual Scientific Meeting of the British-Society-for-Haematology - Manchester Duration: 3 Apr 2022 → 5 Apr 2022

Cite this

Mato, A., Pagel, J., Coombs, C., Shah, N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T., Woyach, J., Wierda, W., Cheah, C., Cohen, J., Roeker, L., Patel, M., Fakhri, B., Barve, M., Tam, C., Lewis, D., Gerson, J., ... Jurczak, W. (2022). Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study. British Journal of Haematology, 197, 97-101.

@article{c1e360f71a0847098dd606fd2f753ca9,

title = "Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study",

author = "Anthony Mato and John Pagel and Catherine Coombs and Nirav Shah and Nicole Lamanna and Talha Munir and Ewa Lech-Maranda and Toby Eyre and Jennifer Woyach and William Wierda and Chan Cheah and Johnathan Cohen and Lindsey Roeker and Manish Patel and Bita Fakhri and Minal Barve and Constantine Tam and David Lewis and James Gerson and Alvaro Alencar and Chaitra Ujjani and Ian Flinn and Suchitra Sundaram and Shuo Ma and Deepa Jagadeesh and Joanna Rhodes and Justin Taylor and Omar Abdel-Wahab and Paolo Ghia and Stephen Schuster and Denise Wang and Binoj Nair and Edward Zhu and Donald Tsai and Matthew Davids and Jennifer Brown and Wojciech Jurczak",

year = "2022",

month = apr,

language = "English",

volume = "197",

pages = "97--101",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons",

note = "2nd Annual Scientific Meeting of the British-Society-for-Haematology ; Conference date: 03-04-2022 Through 05-04-2022",

}

Mato, A, Pagel, J, Coombs, C, Shah, N, Lamanna, N, Munir, T, Lech-Maranda, E, Eyre, T, Woyach, J, Wierda, W, Cheah, C, Cohen, J, Roeker, L, Patel, M, Fakhri, B, Barve, M, Tam, C, Lewis, D, Gerson, J, Alencar, A, Ujjani, C, Flinn, I, Sundaram, S, Ma, S, Jagadeesh, D, Rhodes, J, Taylor, J, Abdel-Wahab, O, Ghia, P, Schuster, S, Wang, D, Nair, B, Zhu, E, Tsai, D, Davids, M, Brown, J & Jurczak, W 2022, 'Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study', British Journal of Haematology, vol. 197, pp. 97-101.

TY - JOUR

T1 - Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL

T2 - 2nd Annual Scientific Meeting of the British-Society-for-Haematology

AU - Mato, Anthony

AU - Pagel, John

AU - Coombs, Catherine

AU - Shah, Nirav

AU - Lamanna, Nicole

AU - Munir, Talha

AU - Lech-Maranda, Ewa

AU - Eyre, Toby

AU - Woyach, Jennifer

AU - Wierda, William

AU - Cheah, Chan

AU - Cohen, Johnathan

AU - Roeker, Lindsey

AU - Patel, Manish

AU - Fakhri, Bita

AU - Barve, Minal

AU - Tam, Constantine

AU - Lewis, David

AU - Gerson, James

AU - Alencar, Alvaro

AU - Ujjani, Chaitra

AU - Flinn, Ian

AU - Sundaram, Suchitra

AU - Ma, Shuo

AU - Jagadeesh, Deepa

AU - Rhodes, Joanna

AU - Taylor, Justin

AU - Abdel-Wahab, Omar

AU - Ghia, Paolo

AU - Schuster, Stephen

AU - Wang, Denise

AU - Nair, Binoj

AU - Zhu, Edward

AU - Tsai, Donald

AU - Davids, Matthew

AU - Brown, Jennifer

AU - Jurczak, Wojciech

PY - 2022/4

Y1 - 2022/4

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000776484300105

M3 - Abstract/Meeting Abstract

SN - 0007-1048

VL - 197

SP - 97

EP - 101

JO - British Journal of Haematology

JF - British Journal of Haematology

Y2 - 3 April 2022 through 5 April 2022

ER -

Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

Other files and links

Cite this